Celldex/CLDX

$51.40

6.57%
-
1D1W1MYTD1YMAX

About Celldex

Celldex Therapeutics, Inc. is a biopharmaceutical company. It is focused on developing therapeutic monoclonal and bispecific antibodies that address diseases for which available treatments are inadequate. Its drug candidates include antibody-based therapeutics, which has the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. Its bispecific platform includes CDX-585 and CDX-527. CDX-585 combines its active PD-1 blockade and anti-ILT4 blockade to prevent immunosuppressive signals in T cells and myeloid cells, respectively. Its other programs include CDX-1140, a fully human agonist monoclonal antibody targeted to CD40.

Ticker

CLDX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Anthony Marucci

Employees

148

Headquarters

Hampton, United States

Celldex Metrics

BasicAdvanced
$2.06B
Market cap
-
P/E ratio
-$2.64
EPS
1.45
Beta
-
Dividend rate

What the Analysts think about Celldex

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
28.13% upside
High $90.00
Low $27.00
$51.40
Current price
$65.86
Average price target

Celldex Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,546.66% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$1.5M
650%
Net income
$-38.2M
25.25%
Profit margin
-2,546.66%
-83.3%

Celldex Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.6%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.62
-$0.65
-$0.81
-$0.83
-
Expected
-$0.63
-$0.67
-$0.68
-$0.74
-$0.74
Surprise
-1.9%
-2.5%
19.37%
11.6%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Celldex stock

Buy or sell Celldex stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing